Inhalation Sciences AB subsidiary Ziccum releases antibody data from successful proof-of-concept test
Used to treat a wide range of diseases, approx. 450 human antibodies are currently being developed—but many are formulated as liquids, risking instability and attrition in clinical trials. Ziccum AB now releases full data from its recent successful proof-of-concept test, showing how LaminarPace dried human antibodies into stable, active dry powders. The data include SEM (Scanning Electron Microscope) images, and more.Ziccum’s spray drying tool LaminarPace has successfully dried proteins before, but this was its first test specifically on antibodies. Ziccum AB CEO Göran Conradson: “This is a